Oculis Holding AG
No SEC Form 4 filings for $OCS in the last 30 days.
See all $OCS insider activity →Oculis Holding AG completed randomization in the PREDICT-1 trial for Licaminlimab, a dry-eye drug. Two-thirds of 176 patients carry a TNFR1 gene variant linked to stronger responses. Topline data is expected by year-end 2026. The company aims to position Licaminlimab as a precision medicine for moderate-to-severe dry eye disease, targeting 1.5+ million U.S. patients.
Oculis Holding AG (OCS) announced that its CEO will present at Eyecelerator @ AAO 2026, discussing Licaminlimab, a novel anti-TNFα candidate for dry eye disease, with topline trial results expected by year-end. The company will also sponsor the Neuro-Ophthalmology Subspecialty Day at AAO 2026. Oculis is focused on neuro-ophthalmology and ophthalmology innovations, with Licaminlimab and Privosegtor as key product candidates.
Oculis Holding AG (Nasdaq: OCS) announced the resignation of director Lionel Carnot from its Board of Directors, effective immediately. Carnot served for nearly a decade, contributing to the company's growth from a private startup to a publicly listed biopharmaceutical firm. His departure is not due to any disagreement with the company. Oculis will begin identifying a successor for Carnot.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning OCS (Oculis Holding AG). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent OCS coverage spans financial news, technology and mergers & acquisitions.
The trial milestone may lift Oculis shares if data are positive, but impact is uncertain until results are released.
The announcement may generate modest interest ahead of the trial readout, but no immediate price catalyst.
The resignation is a governance change with limited immediate market impact.
Analyst upgrade and higher target suggest upside potential.
Deal terms and milestone-linked earnout shares create a near-term re-rating catalyst for OCS, with execution risk into 2027 closings.
AlphAI scores every news story that mentions OCS with an AI model for sentiment and relevance, and aggregates insider trades from Oculis Holding AG's SEC EDGAR Form 4 filings. Figures refresh continuously.
Oculis Holding AG completed randomization in the PREDICT-1 trial for Licaminlimab, a dry-eye drug. Two-thirds of 176 patients carry a TNFR1 gene variant linked to stronger responses. Topline data is expected by year-end 2026. The company aims to position Licaminlimab as a precision medicine for moderate-to-severe dry eye disease, targeting 1.5+ million U.S. patients.
2 min readOculis Holding AG (OCS) announced that its CEO will present at Eyecelerator @ AAO 2026, discussing Licaminlimab, a novel anti-TNFα candidate for dry eye disease, with topline trial results expected by year-end. The company will also sponsor the Neuro-Ophthalmology Subspecialty Day at AAO 2026. Oculis is focused on neuro-ophthalmology and ophthalmology innovations, with Licaminlimab and Privosegtor as key product candidates.
2 min readOculis Holding AG (Nasdaq: OCS) announced the resignation of director Lionel Carnot from its Board of Directors, effective immediately. Carnot served for nearly a decade, contributing to the company's growth from a private startup to a publicly listed biopharmaceutical firm. His departure is not due to any disagreement with the company. Oculis will begin identifying a successor for Carnot.
1 min readH.C. Wainwright raised its price target on Oculis Holding AG (NASDAQ:OCS) to $39 from $26, citing progress in the PREDICT-1 trial for dry eye disease. The stock has fallen 62% in six months. Analysts expect potential peak sales of $1.7 billion for licaminlimab. Oculis also began a Phase 3 trial for privosegtor in optic neuritis. Stifel set a $40 price target.
2 min readOculis Holding AG (OCS) agreed to acquire worldwide rights to Accure Therapeutics’ Privosegtor (ACT-01) and ACT-02. Consideration is $3.8m (or CHF 3.1m) upfront plus up to 2.05m OCS shares, including lockup and milestone earnouts. OCS shares rose in premarket. Deal closes by Feb 28, 2027 (ACT-01) and Mar 31, 2027 (ACT-02).
5 min readOculis Holding AG (OCS) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 Oculis Reports Q2 2026 Financial Results and Provides Company Update • Company pivot to neuro-ophthalmology continues with Privosegtor positioned as lead late-stage asset through the registrational PIONEER program with expansion potential in acute multiple sclerosis
3 min readMitie confirmed it agreed to a 221p-per-share offer from OCS, owned by US private equity Clayton Dubilier & Rice, in a £3.1bn deal to merge immigration removal centre operations and other facilities services. Mitie reported £319m revenue for its immigration and justice division in its latest year. The merger is expected to complete in Q1 2027; Mitie shares rose over 38%.
6 min readEuropean markets rose on Tuesday. Stoxx Europe 600 gained 0.56% to 643.19, with FTSE 100 up 0.58%, DAX up 0.66%, CAC 40 up 0.28%, FTSE MIB up 0.81%, and IBEX 35 up 0.9%. UK unemployment held at 4.9% (ONS). Company moves included Shell, BP, TotalEnergies, ASM International, Infineon, Novartis, Julius Baer, Mitie, and Boliden.
5 min readOculis Holding AG said the first patient was randomized in its FDA-aligned, genotype-based PREDICT-1 registrational trial of licaminlimab for dry eye disease. The randomized, double-masked, vehicle-controlled study plans ~160 patients, targeting a specific TNFR1 genotype; primary endpoint is change in global ocular discomfort severity score at Day 29. About 70% of sites are activated and patients are in run-in.
4 min readOculis Holding AG (Nasdaq: OCS; XICE: OCS) said management will join a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference on June 9 in Miami. The company plans to update its late-stage pipeline, including Privosegtor (FDA Breakthrough Therapy and EMA PRIME for optic neuritis) and Licaminlimab (PREDICT-1 trial for genotype-based dry eye disease).
3 min read
